Serum Galectin-3 as a Non-Invasive Marker for Primary Sclerosing Cholangitis
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25094765 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Ganimete Bajraktari und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg…. Hauptthemen laut MEDLINE: Cholangitis, Sclerosing, Biomarkers, Galectin 3, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Primary sclerosing cholangitis (PSC) is a serious liver disease associated with inflammatory bowel disease (IBD). Galectin-3, an inflammatory and fibrotic molecule, has elevated circulating levels in patients with chronic liver disease and inflammatory bowel disease (IBD). This study aims to clarify whether galectin-3 can differentiate between patients with IBD, PSC, and PSC-IBD. Our study measured serum galectin-3 levels in 38 healthy controls, 55 patients with IBD, and 22 patients with PSC (11 patients had underlying IBD and 11 patients did not), alongside the urinary galectin-3 of these patients and 18 controls. Serum and urinary galectin-3 levels in IBD patients were comparable to those in controls. Among IBD patients, those with high fecal calprotectin, indicating severe disease, exhibited lower serum and elevated urinary galectin-3 levels compared to those with low calprotectin levels. Serum galectin-3 levels were inversely correlated with C-reactive protein levels. PSC patients displayed higher serum and urinary galectin-3 levels than IBD patients, with the highest serum levels observed in PSC patients with coexisting IBD. There was no correlation between serum and urinary galectin-3 levels and laboratory indicators of liver injury in both IBD and PSC patients. In conclusion, this study demonstrates that serum and urinary galectin-3 levels can distinguish IBD from PSC patients, and also reveals higher serum galectin-3 levels in PSC-IBD patients compared to those with isolated PSC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany.
ORCID-Profile: Arne Kandulski, Martina Müller, Christa Buechler
Zitieren
APA
Bajraktari, G., Elger, T., Huss, M., Loibl, J., Albert, A., Kandulski, A., Müller, M., Tews, H. C., & Buechler, C. (2024). Serum Galectin-3 as a Non-Invasive Marker for Primary Sclerosing Cholangitis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25094765
Vancouver
Bajraktari G, Elger T, Huss M, Loibl J, Albert A, Kandulski A, et al. Serum Galectin-3 as a Non-Invasive Marker for Primary Sclerosing Cholangitis. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25094765
BibTeX
@article{Bajraktari2024,
author = {Bajraktari, Ganimete and Elger, Tanja and Huss, Muriel and Loibl, Johanna and Albert, Andreas and Kandulski, Arne and Müller, Martina and Tews, Hauke Christian and Buechler, Christa},
title = {Serum Galectin-3 as a Non-Invasive Marker for Primary Sclerosing Cholangitis},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25094765}
}
EUVIMED